Jason Zemansky is ranked #944 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Jason Zemansky (Bank of America Securities) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Jason Zemansky's stock ratings?

About 54% of Jason's ratings were profitable over a one-year hold, with an average return of +7.8% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Jason Zemansky

BofA

Jason Zemansky

Bank of America Securities

Wall Street Analyst

★★★☆☆

#944

on 13Foresight · ranked by our own returns

54%

Success Rate

+7.8%

Average Return

26 of 48 calls profitable · +4.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Jason Zemansky's ratings turned a profit when each position was held for 1 year — averaging +7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

114 Buy 52 Hold 15 Sell

Jason's Stock Coverage 22 ratings · 2026-07-22

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BIIB Biogen	Jul 21, 2026	HOLD	Strong Buy +22.2% avg upside 52 analysts	$215.00 5.83% Upside	·	·
INSM Insmed	Jul 16, 2026	BUY	Strong Buy +59.6% avg upside 37 analysts	$214.00 97.02% Upside	+1.1%	·
SNDX Syndax Pharmaceuticals	Jul 15, 2026	BUY	Strong Buy +58.8% avg upside 27 analysts	$29.00 28.02% Upside	-3.7%	·
MDGL Madrigal Pharmaceuticals	Jul 13, 2026	HOLD	Strong Buy -11.8% avg upside 32 analysts	$542.00 0.85% Downside	+3.0%	·
BBIO BridgeBio Pharma	Jul 09, 2026	BUY	Strong Buy +12.7% avg upside 34 analysts	$101.00 22.58% Upside	-9.1%	·
LGND Ligand Pharma	Jul 09, 2026	BUY	Strong Buy -16.7% avg upside 15 analysts	$388.00 26.92% Upside	-6.0%	·
CYTK Cytokinetics	Jun 16, 2026	HOLD	Strong Buy +8.2% avg upside 36 analysts	$83.00 2.33% Upside	+7.8%	·
ABOS Acumen Pharmaceuticals	Jun 11, 2026	BUY	Strong Buy +264.0% avg upside 10 analysts	$8.00 258.76% Upside	-6.8%	·
RCKT Rocket Pharmaceuticals	Jun 11, 2026	BUY	Buy +384.3% avg upside 29 analysts	$10.00 194.07% Upside	+28.2%	·
TYRA Tyra Bioscience	Jun 10, 2026	BUY	Strong Buy +37.6% avg upside 17 analysts	$42.00 31.81% Upside	+23.9%	·
EIKN Eikon Therapeutics, Inc.	Jun 03, 2026	BUY	Buy +139.6% avg upside 5 analysts	$32.00 222.92% Upside	+5.5%	·
TVTX Travere Therapeutics	Jun 03, 2026	BUY	Strong Buy -16.7% avg upside 22 analysts	$59.00 4.25% Upside	+25.5%	·
KURA Kura Oncology	Jun 03, 2026	BUY	Strong Buy +139.1% avg upside 26 analysts	$30.00 175.42% Upside	+29.9%	·
KROS Keros Therapeutics	Jun 03, 2026	HOLD	Strong Buy +140.7% avg upside 21 analysts	$20.00 89.25% Upside	+0.7%	·
IKT Inhibikase Therapeutics	Jun 03, 2026	BUY	Strong Buy +170.7% avg upside 8 analysts	$6.00 169.06% Upside	+26.4%	·
LYEL Lyell Immunopharma	Jun 03, 2026	SELL	Buy +90.6% avg upside 10 analysts	$12.00 8.39% Downside	-6.0%	·
RCUS Arcus Biosciences	Apr 21, 2026	HOLD	Strong Buy +17.5% avg upside 20 analysts	$25.00 15.14% Downside	+14.3%	·
HOWL Werewolf Therapeutics	Feb 17, 2026	BUY	Strong Buy +1794.3% avg upside 8 analysts	$7.00 1828.46% Upside	-44.9%	·
BMRN BioMarin Pharmaceutical	Oct 30, 2024	BUY	Strong Buy +59.3% avg upside 52 analysts	—	-22.1%	·
OKUR OnKure Therapeutics	Mar 28, 2024	SELL	Buy +468.3% avg upside 13 analysts	$12.00 187.69% Upside	+73.1%	·
KLRS Kalaris Therapeutics	Dec 26, 2023	SELL	Buy +223.0% avg upside 13 analysts	$1.00 75.31% Downside	+37.0%	·
QTTB Q32 Bio	Nov 17, 2023	HOLD	Buy +285.5% avg upside 24 analysts	—	+226.9%	·

🔒 17 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jason Zemansky — Frequently Asked Questions

How accurate are Jason Zemansky's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Jason's ratings were profitable over a one-year hold, with an average return of +7.8% per rating, or +4.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Jason ranked on 13Foresight?

Jason Zemansky is currently ranked #944 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jason cover?

Jason most recently has ratings on BIIB, INSM, SNDX, MDGL, BBIO, LGND, CYTK, ABOS, RCKT, TYRA, EIKN, TVTX and 10 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!